Metastatic Pancreatic Cancer
Conditions
Keywords
metastatic pancreatic cancer, real world data, gemcitabine, nabpaclitaxel, efficacy, safety
Brief summary
Retrospective, multicenter study including pts with metastatic pancreatic cancer who started first-line treatment with napaclitaxel plus Gemcitabine between December 2013 and June 2015 according to the routine practice. Overall survival (OS) and progression-free survival (PFS) were assessed for the total sample and the exploratory subgroups based on treatment and clinical characteristics of the study pts.
Detailed description
This observational, retrospective, multicenter study included patients with metastatic pancreatic adenocarcinoma (either recurrent or de novo) from 20 Spanish hospitals, who started first-line chemotherapy with nab-paclitaxel (Abraxane®, Celgene Europe Limited) plus gemcitabine between December 2013 and June 2015 according to routine clinical practice. The record included all adult patients (i.e., aged ≥ 18 years) with measurable metastatic disease at baseline in at least one dimension of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1,\[15\] who received at least one dose of combined treatment with nab-paclitaxel plus gemcitabine. Data were retrieved from patients' medical records and lasted until death or the closure of the database on 16 March 2017. All patients signed the corresponding informed consent for their clinical data being used in this study, which was conducted in accordance with the local personal data protection law (LOPD 15/1999). The study protocol was approved by the local independent ethics committee.
Interventions
DRUGGemcitabine - nabpaclitaxel
efficacy and safety
Sponsors
Galician Research Group on Digestive Tumors
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically-confirmed pancreatic adenocarcinoma or poorly differentiated carcinoma that is metastatic to distant sites. * Other histologies such as neuroendocrine and acinar cell carcinoma are excluded. * No prior chemotherapy for metastatic pancreatic cancer. * Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. * Age greater than or equal to 18 years. * Patient has signed a Patient Informed Consent Form. * Patients should have received at least one cycle of gemcitabine and nabpaclitaxel
Exclusion criteria
* less than one cycle of gemcitabine/nabpaclitaxel administrated.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 2 years | Evaluate overall survival (OS) in patients with metastatic pancreatic cancer receiving gemcitabine and nab-paclitaxel |
| progression free survival | 2 years | Evaluate progression free survival (PFS) in patients with metastatic pancreatic cancer receiving gemcitabine and nab-paclitaxel |
| Assess adverse events (per CTCAE v4.0 criteria) | 2 years | Assess the adverse events (per CTCAE v4.0 criteria) associated with the use of gemcitabine and nab-paclitaxel in real world setting. |
Outcome results
None listed